



# Doctoral Candidate (DC14): Circulating Proteomic Biomarkers for Early Breast Cancer Detection and Treatment Response

Marie Skłodowska-Curie Doctoral Network (HER-CARE)

**Host organisation:** Proteotype Diagnostics Ltd (UK)

**Academic partner:** Medical University of Vienna (Austria)

**Position:** Doctoral Candidate (DC14)

**Duration:** 36 months

**Expected start date:** Autumn 2026

---

## Project Overview

Proteotype Diagnostics is recruiting a **Doctoral Candidate (DC14)** as part of the **HER-CARE Marie Skłodowska-Curie Doctoral Network**, a European programme training the next generation of researchers in hereditary and early-stage breast cancer.

The project will focus on the development of **circulating proteomic biomarkers for early breast cancer detection and prediction of treatment response**, using Proteotype's proprietary biomarker platform.

The doctoral candidate will:

- Investigate detection of **early-stage (Stage I–III) breast cancer**
- Analyse biomarker dynamics during **systemic and neoadjuvant therapies**
- Predict **pathological complete response (pCR)**
- Integrate **proteomic, clinical, and epidemiological datasets**
- Contribute to translational and mechanistic understanding of biomarker signals

Selected samples will also undergo **advanced LC-MS proteomic analysis** in collaboration with the **Medical University of Vienna**.

---

## Training and Supervision

The doctoral candidate will:

- Be employed by **Proteotype Diagnostics**
- Be enrolled as a **PhD candidate at the Medical University of Vienna**
- Be supervised by **Dr. Yen Tan** (primary academic supervisor)
- Receive industrial supervision from Proteotype
- Participate in the HER-CARE doctoral training programme, including international collaboration and secondments



## Candidate Profile

We are seeking a highly motivated candidate with strong quantitative and interdisciplinary skills.

Essential:

- MSc (or equivalent) in **bioinformatics, computational biology, molecular biology, biomedical sciences, data science or related field**
- Experience in **data analysis, statistics, or computational methods**
- Programming skills in **Python, R or similar**
- Interest in **translational cancer research and biomarker development**

Desirable:

- Experience in **proteomics, machine learning, or multi-omics data integration**
- Background in **oncology or clinical data analysis**

---

## Eligibility Criteria (MSCA Requirements)

Applicants must:

- Not already hold a **doctoral degree (PhD)**
- Be eligible to enrol in a PhD programme at the Medical University of Vienna

### **Mobility rule (mandatory):**

Applicants must **not have resided or carried out their main activity** (work, studies, etc.) in the United Kingdom for more than **12 months** in the 36 months immediately before the recruitment date.

---

## What We Offer

- Fully funded **36-month** doctoral position
- Salary and benefits in line with **MSCA Doctoral Network funding rules**
- Interdisciplinary research training across Europe
- Collaboration with leading academic and clinical partners
- Opportunity to work on **cutting-edge liquid biopsy technologies**



## Application Process

Apply via LinkedIn <https://www.linkedin.com/jobs/view/4399458149/> or via our website <https://proteotype.com/careers>

**April 20th to 24th: Initial Screening Call:** Shortlisted candidates will be invited to a 30-minute call to discuss their background, the role, and answer any initial questions.

**April 27th to May 1st: Interview Stage:** Successful candidates will progress to further interview(s), which may include:

- A technical/skills-based interview
- A conversation with key team members/stakeholders

**May 4 to 8: Final Stage:** The final interview with senior stakeholders, and may involve a case study or presentation, after which we will make a decision, and an offer will be made.

The position will be advertised via **EURAXESS and HER-CARE recruitment channels.**

---

## EU Funding Acknowledgement

This project is funded by the European Union under the Marie Skłodowska-Curie Actions (MSCA).